Interna Therapeutics

Company Overview

Snapshot

Founded in October 1996 by Ilan Ziv, MD, Interna Therapeutics operates with 11–50 employees. The company has raised a total of $57.55 million across 5 funding rounds from 10 investors. In November 2024, Interna Therapeutics merged with SirVir and secured a funding round led by the Bill &.

Business overview

Interna Therapeutics is a biotechnology company specializing in advanced drug delivery. The company has developed Molecular Nano-Motors (MNMs), a proprietary technology that utilizes membrane electrical forces to facilitate the intracellular entry of charged macromolecules, such as oligonucleotide-based drugs (siRNA, ASO). This technology aims to enable new treatment options for a wide range of diseases by overcoming delivery challenges for difficult-to-deliver molecules. Interna Therapeutics operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drug Delivery, serving the pharmaceutical industry.

Strategic signal

In April 2026, Interna Therapeutics announced a research collaboration with Daiichi Sankyo to advance its MNM-based targeted delivery technologies. This partnership signals significant external validation of Interna's core technology and its potential to address critical unmet needs in drug delivery, indicating a strong growth trajectory and strategic interest from established pharmaceutical players.

Company Intelligence Q&A

What was the most recent strategic partnership for Interna Therapeutics?

In April 2026, Interna Therapeutics announced a research collaboration with Daiichi Sankyo. This partnership focuses on advancing Interna's Molecular Nano Motor (MNM) intracellular delivery platform for targeted delivery technologies.

What significant corporate event occurred for Interna Therapeutics in November 2024?

In November 2024, Interna Therapeutics merged with SirVir and simultaneously secured a funding round led by the Bill &. This event also marked the company's name change to Interna Therapeutics.

When did Interna Therapeutics initiate a Phase I study for a COVID-19 drug?

Interna Therapeutics began a Phase I study for a COVID-19 drug in September 2024, leveraging its Molecular Nano-Motors (MNMs) technology.

What was the nature of the collaboration between Bioasis Technologies Inc. and Aposense (now Interna Therapeutics) in March 2021?

In March 2021, Bioasis Technologies Inc. and Aposense (now Interna Therapeutics) entered into a research collaboration focused on the delivery of siRNA into the brain. The goal was to advance the discovery and development of new siRNA-based drugs for neurological conditions, utilizing Bioasis's blood-brain barrier technology and Aposense's expertise.

What was the licensing agreement between Processa Pharmaceuticals and Aposense (now Interna Therapeutics) in June 2020?

In June 2020, Processa Pharmaceuticals entered into a licensing agreement with Aposense (now Interna Therapeutics) to develop and commercialize ATT-11T, a next-generation irinotecan cancer drug. Under the terms, Aposense was to receive shares in Processa valued at $2.5 million and could receive up to $125 million in potential development and sales milestones, plus 7% royalties on net sales.